Delaware |
001-35312
|
68-0533453
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated August 8, 2017, reporting the Company’s financial results for the quarter ended June 30, 2017
|
Date: August 8, 2017
|
CHF SOLUTIONS, INC.
|
||
By:
|
/s/ Claudia Drayton
|
||
Name:
|
Claudia Drayton
|
||
Title:
|
Chief Financial Officer
|
Exhibit Number
|
Description
|
|
Press Release, dated August 8, 2017, reporting the Company’s financial results for the quarter ended June 30, 2017
|
• |
Revenue for second quarter ended June 30, 2017 increased 18% compared to the same period in 2016 when the business was under previous ownership.
|
• |
New sales leadership on board focusing on building a direct field organization, increasing account penetration and utilization, driven by strong account training and servicing.
|
• |
Stanford University FDA approval for IDE clinical trial using Aquadex FlexFlow System to treat pediatric patients.
|
• |
Transition of Aquadex FlexFlow System manufacturing from Baxter to in-house operations. Manufacturing in house expected to commence in the fourth quarter of 2017.
|
• |
Completed an underwritten public equity offering for net proceeds of approximately $8.0 million. Reduced operating expenses by 31% compared to the same quarter of 2016. Ended quarter with cash on hand of $5.6 million.
|
• |
Announced a name change from Sunshine Heart, Inc. to CHF Solutions, Inc. to capitalize on brand recognition and goodwill, and to more appropriately reflect the direction of the business.
|
Three months ended
June 30,
|
Six months ended
June 30,
|
|||||||||||||||
2017
|
2016
|
2017
|
2016
|
|||||||||||||
Net sales
|
$
|
864
|
$
|
-
|
$
|
1,765
|
$
|
-
|
||||||||
Costs and expenses:
|
||||||||||||||||
Cost of goods sold
|
616
|
-
|
1,130
|
-
|
||||||||||||
Selling, general and administrative
|
2,420
|
1,412
|
4,807
|
2,761
|
||||||||||||
Research and development
|
327
|
2,570
|
635
|
5,776
|
||||||||||||
Total costs and expenses
|
3,363
|
3,982
|
6,572
|
8,537
|
||||||||||||
Loss from operations
|
(2,499
|
)
|
(3,982
|
)
|
(4,807
|
)
|
(8,537
|
)
|
||||||||
Other income (expense):
|
||||||||||||||||
Interest expense
|
-
|
(207
|
)
|
-
|
(436
|
)
|
||||||||||
Other income (expense), net
|
5
|
(1
|
)
|
11
|
-
|
|||||||||||
Warrant valuation expense
|
-
|
-
|
(67
|
)
|
-
|
|||||||||||
Change in fair value of warrant liability
|
37
|
-
|
1,466
|
-
|
||||||||||||
Total other income (expense)
|
42
|
(208
|
)
|
1,410
|
(436
|
)
|
||||||||||
Loss before income taxes
|
(2,457
|
)
|
(4,190
|
)
|
(3,397
|
)
|
(8,973
|
)
|
||||||||
Income tax benefit (expense), net
|
(1
|
)
|
2
|
(1
|
)
|
(1
|
)
|
|||||||||
Net loss
|
$
|
(2,458
|
)
|
$
|
(4,188
|
)
|
$
|
(3,398
|
)
|
$
|
(8,974
|
)
|
||||
Basic and diluted loss per share
|
$
|
(0.47
|
)
|
$
|
(6.83
|
)
|
$
|
(1.39
|
)
|
$
|
(14.64
|
)
|
||||
Weighted average shares outstanding – basic and diluted
|
7,430
|
613
|
4,505
|
613
|
||||||||||||
Other comprehensive income:
|
||||||||||||||||
Foreign currency translation adjustments
|
$
|
(5
|
)
|
$
|
(2
|
)
|
$
|
(6
|
)
|
$
|
(6
|
)
|
||||
Total comprehensive loss
|
$
|
(2,463
|
)
|
$
|
(4,190
|
)
|
$
|
(3,404
|
)
|
$
|
(8,980
|
)
|
June 30,
2017
(unaudited)
|
December
31, 2016
|
|||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
5,558
|
$
|
1,323
|
||||
Accounts receivable
|
618
|
282
|
||||||
Inventory
|
864
|
677
|
||||||
Other current assets
|
129
|
137
|
||||||
Total current assets
|
7,169
|
2,419
|
||||||
Property, plant and equipment, net
|
446
|
540
|
||||||
Intangible assets, net
|
3,980
|
4,302
|
||||||
Goodwill
|
189
|
189
|
||||||
Other assets
|
21
|
21
|
||||||
TOTAL ASSETS
|
$
|
11,805
|
$
|
7,471
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Accounts payable and accrued expenses
|
$
|
1,520
|
$
|
2,351
|
||||
Accrued compensation
|
644
|
909
|
||||||
Total current liabilities
|
2,164
|
3,260
|
||||||
Common stock warrant liability
|
10
|
1,843
|
||||||
Other liabilities
|
126
|
126
|
||||||
Total liabilities
|
2,300
|
5,229
|
||||||
Commitments and contingencies
|
—
|
—
|
||||||
Temporary Stockholders’ Equity
|
||||||||
Series D convertible preferred stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 0 and 900 shares, respectively, issued and outstanding 0 and 700, respectively
|
—
|
485
|
||||||
Stockholders’ equity
|
||||||||
Series A junior participating preferred stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 30,000 shares, none outstanding
|
—
|
—
|
||||||
Series B-1 convertible preferred stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 0 and 1,824.4 shares, respectively, issued and outstanding 0 and 1,824.4, respectively
|
—
|
—
|
||||||
Series C convertible preferred stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 0 and 2,900 shares, respectively, issued and outstanding 0 and 2,900, respectively
|
—
|
—
|
||||||
Preferred stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 39,970,000 and 39,964,375.6 shares, respectively, none outstanding
|
—
|
—
|
||||||
Common stock as of June 30, 2017 and December 31, 2016, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 12,321,238 and 777,238, respectively
|
1
|
—
|
||||||
Additional paid‑in capital
|
180,647
|
169,496
|
||||||
Accumulated other comprehensive income:
|
||||||||
Foreign currency translation adjustment
|
1,229
|
1,235
|
||||||
Accumulated deficit
|
(172,372
|
)
|
(168,974
|
)
|
||||
Total stockholders’ equity
|
9,505
|
1,757
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
11,805
|
$
|
7,471
|
Six months ended
June 30,
|
||||||||
2017
|
2016
|
|||||||
Operating Activities:
|
||||||||
Net loss
|
$
|
(3,398
|
)
|
$
|
(8,974
|
)
|
||
Adjustments to reconcile net loss to cash flows used in operating activities:
|
||||||||
Depreciation and amortization expense
|
436
|
152
|
||||||
Stock-based compensation expense, net
|
281
|
499
|
||||||
Amortization of debt discount and financing fees
|
-
|
162
|
||||||
Change in fair value of warrant liability
|
(1,466
|
)
|
-
|
|||||
Warrant valuation expense
|
67
|
-
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(336
|
)
|
-
|
|||||
Inventory
|
(187
|
)
|
-
|
|||||
Other current assets
|
8
|
197
|
||||||
Other assets
|
-
|
25
|
||||||
Accounts payable and accrued expenses
|
(1,103
|
)
|
(1,197
|
)
|
||||
Net cash used in operations
|
(5,698
|
)
|
(9,136
|
)
|
||||
Investing Activities:
|
||||||||
Purchases of property and equipment
|
(20
|
)
|
(29
|
)
|
||||
Net cash used in investing activities
|
(20
|
)
|
(29
|
)
|
||||
Financing Activities:
|
||||||||
Net proceeds from public stock offering
|
8,002
|
-
|
||||||
Net proceeds from exercise of warrants
|
1,768
|
-
|
||||||
Net proceeds from the sale of preferred stock and warrants
|
184
|
-
|
||||||
Repayments on borrowings on long-term debt
|
-
|
(1,895
|
)
|
|||||
Net cash (used in) provided by financing activities
|
9,954
|
(1,895
|
)
|
|||||
Effect of exchange rate changes on cash
|
(1
|
)
|
(4
|
)
|
||||
Net increase (decrease) in cash and cash equivalents
|
4,235
|
(11,064
|
)
|
|||||
Cash and cash equivalents - beginning of period
|
1,323
|
23,113
|
||||||
Cash and cash equivalents - end of period
|
$
|
5,558
|
$
|
12,049
|
||||
Supplement schedule of non-cash activities
|
||||||||
Warrants issued as inducement to warrant exercise
|
$
|
509
|
$
|
-
|
||||
Conversion of temporary equity to permanent equity
|
$
|
485
|
$
|
-
|
||||
Supplemental cash flow information
|
||||||||
Interest paid on debt borrowings
|
$
|
-
|
$
|
257
|
Claudia Napal Drayton
|
Investor Relations
|
Chief Financial Officer
|
CHF Solutions, Inc.
|
CHF Solutions, Inc.
|
ir@chf-solutions.com
|
T: +1-952-345-4205
|
Bret Shapiro
|
Managing Partner
|
CORE IR
|
516 222 2560
|
brets@coreir.com
|
www.coreir.com
|